Current Perspectives of the Use of Sodium–Glucose Transport-2 Inhibitors for Patients With Heart Failure and Chronic Kidney Disease

Abstract

Sodium–glucose cotransporter-2 inhibitors (SGLT-2 inhibitors) are a relatively new class of drugs approved for the treatment of type 2 diabetes. In 2021, the American College of Cardiology recommended the use of SGLT-2 inhibitors in patients with heart failure (HF), with or without type 2 diabetes, because of their morbidity and mortality benefits. The review provides an overview of the efficacy and safety of SGLT-2 inhibitors in HF and chronic kidney disease (CKD). We review the existing literature for SGLT-2 inhibitors by searching PubMed.gov using the keywords SGLT-2 inhibitors, HF, and CKD. A clinical treatment pathway is provided to help guide clinicians in choosing an SGLT-2 inhibitor for their patients with chronic HF and CKD.